AstraZeneca hit with second blow on $2.7 billion drug
March 17, 2017Medical Communications AstraZeneca, FDA, hyperkalaemia
AstraZeneca paid $2.7 billion for ZS Pharma, back in 2015, with the desire to get its hands on the company’s …
Biogen swoops to appoint Ex-Roche Vice President
March 16, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen
Biogen have appointed Anirvan Ghosh to the position of Senior Vice President of research and Early Development. Ghosh is slated …
NICE reverses decision on medication for relapsing multiple sclerosis
March 16, 2017Sales and Marketing Biogen, zinbryta
The current topic of discussion regarding NICE is how its recent changes will impact patient access to medicine but, away …
The rising threat of antibiotic resistance
March 16, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing antibiotic resistance
Last month, researchers from the University of California, Los Angeles (UCLA) revealed findings that showed that utilising antibiotics in combination …
NICE drug expense limit of £20 million could cause treatment delays
March 16, 2017Medical Communications, Sales and Marketing NHS England, NICE, fast-track appraisal process, rare disease
NICE has released its decision on the fast-track approval process and other changes that will be brought through at the …
FDA warns China’s Lumis over misbranded APIs
March 16, 2017Manufacturing and Production FDA, Lumis
Chinese firm Lumis Global Pharmaceuticals became the latest to face the FDA’s ire as it was hit by a warning …
US city takes drug company to court over opioid crisis
March 16, 2017Medical Communications OxyContin, opioid, opioid crisis
The opioid crisis in North America continues to rumble on, ruining lives and causing untold damage to communities. One city, …
Trump’s proposed budget doubles FDA regulatory fees
March 16, 2017Sales and Marketing FDA, Trump
Trump’s presidency could cost the industry more than twice as much in regulatory review fees next year, as his administration …
Ibuprofen linked to 31% increase in risk of cardiac arrest
March 16, 2017Medical Communications cardiac arrest, ibuprofen
A study emerging from Denmark has found that the use of over-the-counter pain killer, Ibuprofen, is associated with an increased …
SHL to Present at Pharmapack Symposium Taiwan 2017
March 16, 2017Manufacturing and Production auto injectors, extractables and leachables, prefilled syringe
Olle Ljungquist, Senior Scientist at SHL Group, will give a talk on the “Requirements and Test Methods for Finished Prefilled …
Decade lifespan difference in Americans and Canadians with cystic fibrosis
March 15, 2017Research and Development Canada, United States, cystic fibrosis
A new study has emerged looking into life expectancy of those with cystic fibrosis, funded by the US Cystic Fibrosis …
NICE recommends against Opdivo for classical Hodgkin lymphoma
March 15, 2017Research and Development, Sales and Marketing BMS, classical Hodgkin Lymphoma, opdivo
The National Institute of Health and Care Excellence (NICE) has released draft guidance provisionally turning down Bristol-Myers Squibb’s Opdivo (nivolumab) …
FDA-approved preterm birth drug has no benefit and may cause harm, study suggests
March 15, 2017Research and Development FDA, Makena
A study by the UT Southwestern Medical Center has found that the synthetic progestogen hormone 17-alpha hydroxyprogesterone caproate (17-OHPC), a …
MSD’s Keytruda notches another FDA approval in Hodgkin lymphoma
March 15, 2017Research and Development, Sales and Marketing Hodgkin lymphoma, MSD, keytruda
MSD, otherwise known as Merck in North America, continues to score indication successes with Keytruda, this time in Hodgkin lymphoma. …
Patients in UK to be given early access to Sanofi’s eczema treatment
March 14, 2017Research and Development, Sales and Marketing Dupilumab, MHRA, Sanofi
Sanofi’s treatment for atopic dermatitis, otherwise known as eczema, has been given a positive scientific opinion through the MHRA’s Early …
Novartis secures first-line FDA approval in breast cancer indication
March 14, 2017Manufacturing and Production, Sales and Marketing Kisqali, Novartis, breast cancer
The FDA has approved Kisqali (ribociclib) in combination with letrozole for the first-line treatment of postmenopausal women with hormone receptor …
Survivors of Hodgkin lymphoma over twice as likely to suffer second cancer
March 14, 2017Manufacturing and Production, Research and Development Hodgkin lymphoma, ICR
New research emerging from the Institute for Cancer Research (ICR) has found that those previously treated for Hodgkin lymphoma are …
FDA lifts block on Sun Pharma facility
March 14, 2017Manufacturing and Production FDA, Sun Pharma
Sun Pharma has announced that the FDA informed it that the Import Alert in place upon its Mohali manufacturing facility …
One in five women with breast cancer could benefit from existing therapy
March 14, 2017Manufacturing and Production, Research and Development Wellcome Trust Sanger Institute, breast cancer, parp inhibitors
A new study emerging from the Wellcome Trust Sanger Institute has discovered that there are more cases of breast cancer …
XTuit Pharmaceuticals move to appoint biotech veteran as CEO
March 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing XTuit Pharmaceuticals
XTuit Pharmaceuticals has revealed the appointment of Deborah Dunshire as its new President and CEO. XTuit Pharmaceuticals is a biotech …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
